Share on StockTwits
 

GlaxoSmithKline (LON:GSK)‘s stock had its “neutral” rating reiterated by analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Tuesday, Stock Ratings News reports. They currently have a GBX 1,750 ($28.84) price objective on the stock. JPMorgan Chase & Co.’s target price indicates a potential upside of 9.27% from the company’s current price.

Shares of GlaxoSmithKline (LON:GSK) traded down 0.56% during mid-day trading on Tuesday, hitting GBX 1601.50. 5,363,320 shares of the company’s stock traded hands. GlaxoSmithKline has a one year low of GBX 1405.00 and a one year high of GBX 1816.00. The stock’s 50-day moving average is GBX 1602. and its 200-day moving average is GBX 1625.. The company’s market cap is £77.144 billion.

A number of other firms have also recently commented on GSK. Analysts at S&P Equity Research upgraded shares of GlaxoSmithKline to a “hold” rating in a research note to investors on Monday. They now have a GBX 1,680 ($27.68) price target on the stock, up previously from GBX 1,400 ($23.07). Separately, analysts at Deutsche Bank reiterated a “hold” rating on shares of GlaxoSmithKline in a research note to investors on Friday. They now have a GBX 1,700 ($28.01) price target on the stock. Finally, analysts at Cowen and Company downgraded shares of GlaxoSmithKline to a “market perform” rating in a research note to investors on Wednesday, January 22nd. Five research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of GBX 1,703.98 ($28.08).

GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.